Swiss National Bank Buys 300 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Swiss National Bank raised its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 0.8% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 39,800 shares of the medical instruments supplier’s stock after purchasing an additional 300 shares during the quarter. Swiss National Bank’s holdings in LeMaitre Vascular were worth $3,667,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Smartleaf Asset Management LLC boosted its holdings in shares of LeMaitre Vascular by 234.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier’s stock worth $39,000 after purchasing an additional 293 shares in the last quarter. KBC Group NV lifted its position in LeMaitre Vascular by 58.4% in the 4th quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier’s stock worth $102,000 after buying an additional 410 shares during the last quarter. Empowered Funds LLC purchased a new stake in LeMaitre Vascular in the fourth quarter worth approximately $150,000. SG Americas Securities LLC bought a new position in LeMaitre Vascular during the fourth quarter valued at approximately $158,000. Finally, Advisors Asset Management Inc. raised its stake in shares of LeMaitre Vascular by 180.2% during the third quarter. Advisors Asset Management Inc. now owns 1,852 shares of the medical instruments supplier’s stock worth $172,000 after acquiring an additional 1,191 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Price Performance

NASDAQ LMAT opened at $85.08 on Wednesday. LeMaitre Vascular, Inc. has a 1-year low of $62.39 and a 1-year high of $109.58. The stock has a market capitalization of $1.92 billion, a price-to-earnings ratio of 46.49, a PEG ratio of 2.22 and a beta of 0.89. The business’s fifty day moving average price is $93.94 and its 200-day moving average price is $94.48.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, hitting the consensus estimate of $0.49. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The firm had revenue of $55.81 million for the quarter, compared to the consensus estimate of $55.99 million. Equities research analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 27th. Stockholders of record on Thursday, March 13th will be given a dividend of $0.20 per share. The ex-dividend date of this dividend is Thursday, March 13th. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.16. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.94%. LeMaitre Vascular’s dividend payout ratio (DPR) is 41.24%.

Insider Activity at LeMaitre Vascular

In related news, insider Trent G. Kamke sold 2,009 shares of the company’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total transaction of $164,979.08. Following the transaction, the insider now directly owns 5,564 shares of the company’s stock, valued at $456,915.68. This represents a 26.53 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 10.79% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on LMAT shares. Oppenheimer cut shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Wells Fargo & Company assumed coverage on shares of LeMaitre Vascular in a research report on Thursday, February 13th. They set an “equal weight” rating and a $95.00 price target for the company. StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Barrington Research cut LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Finally, Lake Street Capital lifted their price target on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Five analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $95.25.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.